United States AI in Drug Discovery and Development Market to hit US$ 10.21 Billion by 2033 | Top Companies - Alphabet (Google DeepMind), Atomwise Inc., BenevolentAI

Leander, Texas and Tokyo, Japan - Jan.02.2026
As per DataM intelligence research report" The Global AI in drug discovery and development market reached US$ 6.24 billion in 2024 and is expected to reach US$ 34.05 billion by 2033, growing at a CAGR of 18.5% during the forecast period 2025-2033." Faster molecule identification, predictive modeling, and reduced R&D timelines are fueling AI use in drug discovery.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?prasad

United States: Recent Industry Developments

✅ In November 2025, NVIDIA launched "BioNeMo 2.0" with enhanced protein folding capabilities The generative AI cloud service allows researchers to simulate drug-target interactions at unprecedented speed It lowers the barrier to entry for smaller U.S. biotech firms

✅ In October 2025, Recursion Pharmaceuticals announced a major dataset update for its AI map of biology The update includes millions of new cellular images to train more accurate predictive models It accelerates the identification of novel targets for rare diseases

✅ In September 2025, Isomorphic Labs (Alphabet) entered a strategic partnership with a major U.S. pharma giant The collaboration focuses on designing small molecules for "undruggable" cancer targets It validates the commercial potential of "Digital Biology" in the U.S.

✅ In August 2025, Insilico Medicine initiated a Phase 2 trial for an AI-discovered fibrosis drug The drug is the first entirely AI-generated molecule to reach mid-stage clinical trials It marks a milestone for the validation of AI pipelines in U.S. drug development

Japan: Recent Industry Developments

✅ In December 2025, Fujitsu integrated its "Fugaku" supercomputer with a new generative AI for drug discovery The system simulates molecular dynamics of protein-drug binding with high fidelity It supports Japan's national project to create innovative pharmaceuticals

✅ In November 2025, Takeda Pharmaceutical deployed an AI agent to automate the analysis of clinical trial data The tool identifies patient subgroups that respond best to treatment, optimizing trial success It improves the efficiency of R&D in Japan's leading pharma company

✅ In October 2025, Ono Pharmaceutical partnered with a local AI startup to find new immunotherapy targets The partnership uses AI to analyze the tumor microenvironment from patient tissue samples It strengthens Japan's position in the oncology drug market

✅ In September 2025, NEC Corporation launched an AI vaccine design platform The platform predicts viral mutations to design vaccines that remain effective longer It enhances Japan's preparedness for future infectious disease threats

AI in Drug Discovery and Development Market: Drivers
The AI in drug discovery and development market is growing rapidly as pharmaceutical companies seek to accelerate R&D timelines and reduce costs. Machine learning and predictive modeling improve candidate molecule selection and optimize clinical trial design. Rising prevalence of chronic diseases and complex therapeutic areas increases the need for efficient drug development solutions. Integration of AI with genomics, proteomics, and bioinformatics enhances precision medicine applications. Increasing investments by biotech firms and venture capitalists support innovation. Regulatory agencies are providing frameworks to encourage AI-assisted drug development.

Collaborative partnerships between AI providers and pharmaceutical companies strengthen adoption. Automation of preclinical and clinical processes reduces time-to-market and operational costs. AI-driven predictive toxicology and molecular simulations enhance safety and efficacy profiles. Growing demand for personalized medicine and targeted therapies fuels R&D applications. Expansion of cloud computing and big data analytics supports scalable AI integration. Overall, AI in drug discovery is transforming pharmaceutical development and accelerating innovative therapies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?prasad

AI in Drug Discovery and Development Market: Major Players
Alphabet (Google DeepMind), Atomwise Inc., BenevolentAI, BioMap, BioSymetrics, DEEP Genomics, Euretos, Exscientia, IBM, and Iktos. Among others.

Segment Covered in the AI in Drug Discovery and Development Market:
By Technology
The market is segmented into Machine Learning & Deep Learning 50%, Natural Language Processing (NLP) 25%, Predictive Analytics 15%, and Others 10%.
Machine learning and deep learning dominate due to their ability to analyze large datasets, identify potential drug candidates, and optimize clinical trial designs. NLP is growing with adoption in literature mining, patent analysis, and real-world data extraction. Predictive analytics helps in modeling drug efficacy, safety, and patient responses. Other technologies include computer vision and reinforcement learning for molecular simulations.

By Application
Applications include Target Identification & Validation 30%, Drug Design & Screening 25%, Preclinical & Clinical Development 20%, Pharmacovigilance & Safety Assessment 15%, and Others 10%. Target identification dominates as AI accelerates identification of disease pathways and biomarkers. Drug design and screening are growing due to high-throughput virtual screening and molecular modeling. Preclinical and clinical development benefit from trial design optimization and patient stratification. Pharmacovigilance uses AI for adverse event monitoring and safety assessment.

Regional Analysis
North America - 40% Share
North America leads with 40% share, driven by strong pharmaceutical R&D investments, advanced AI infrastructure, and high adoption of AI tools in drug discovery in the U.S. and Canada.

Europe - 25% Share
Europe accounts for 25% share, supported by growing biotech R&D, regulatory support for AI-driven innovation, and strong adoption in the UK, Germany, and Switzerland.

Asia Pacific - 25% Share
Asia Pacific holds 25% share, driven by emerging pharmaceutical and biotech hubs in China, India, and Japan, increasing investment in AI platforms, and growing adoption of smart laboratory solutions.

Latin America - 5% Share
Latin America represents 5% share, with growth fueled by early-stage biotech R&D, academic collaborations, and increasing AI adoption in Brazil and Mexico.

Middle East & Africa - 5% Share
Middle East & Africa account for 5% share, driven by rising investment in healthcare technology, emerging biotech ecosystems, and partnerships in UAE, Saudi Arabia, and South Africa.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.